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1. Introduction 
Multifunctional mast cells (MC) have been recently reported as effectors in the human 
innate and even adaptive immune system, besides their known roles in allergic disorders. 
First in vivo observations in the 1950`s suggested their possible role as anti-tumor cells 
around certain solid tumors and questioned their interactions with tumor cells (Prior, 1953). 
Later, in vitro murine mast cell cytotoxicity (MCC) against murine tumor cells was 
described in 1981 (Henderson, 1981; Ghiara, 1985; Richards 1988).  However, to the best of 
our knowledge, there is no reported data on in vitro human MCC against human tumor 
cells. Current in vivo observations and implications from human pathological specimens are 
also very controversial. Moreover, there is still difficulty in obtaining and maintaining 
human MCs in cultures since they have low expansion potential. These facts have hampered 
in vitro human MC studies up to the last decades of the 20th century. The recent use of 
methylcellulose media for in vitro human MC cultures increased the knowledge and data 
strongly supporting an increasing role of MC as effector elements of innate immunity 
(Leskinen, 2003; Marshall, 2004; Della Rovere, 2009; Özdemir, 2007, 2011). 
Ambiguous and mounting evidence also indicates that MCs accumulate around tumors and 
could either promote or inhibit tumor growth, most likely depending on environmental 
conditions. Presently, believers in the inhibitory role of MCs assume them to be inhibitors of 
tumor development through their cytotoxic pro-necrolytic/-apoptotic granules (Wagelie-
Steffen, 1998; Leskinen, 2003; Kataoka, 2004; Pardo, 2007; Heikkilä, 2008). In fact, the MC has 
been long believed to have natural cytotoxicity against murine TNF-α sensitive tumor cells 
in the long term incubations (>24h), by either TNF-α dependent or independent pathways. 
TNF-α independent pathways like cathepsin G, NO, serine proteases, peroxidases, H2O2 etc. 
were also assumed to contribute to MCC (Henderson, 1981; Ghiara, 1985; Richards 1988).  
Moreover, in vitro murine MCC has been well demonstrated against TNF-α-sensitive 
murine WEHI-164 and L929 tumor cells. Murine MCC seems to be different from natural 
killer (NK) cytotoxicity by means of acting in long term against unusual targets such as 
WEHI-164 and L929 with different mediators like peroxidases (Henderson, 1981; Ghiara, 
1985; Richards 1988).  Moreover, the last decade of research demonstrates that MC granules 
have pro-apoptotic characteristics (Wagelie-Steffen, 1998; Leskinen, 2003; Kataoka, 2004; 
Pardo, 2007; Heikkilä, 2008). Chymase was shown to induce apoptosis, and apoptotic 
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pathway mediators such as FasL and granzyme B expressions were detected in mice and 
cultured MCs; respectively (Wagelie-Steffen, 1998; Leskinen, 2003; Kataoka, 2004; Pardo, 
2007; Heikkilä, 2008). Thus, except for perforin (Pardo, 2007), MCs indeed have been proven 
to have all components of short and long-term cell-mediated cytotoxicity, which consist of 
the secretory pathway (via soluble TNF-α, chymase, serine proteases granzyme-B/-H), and 
non-secretory pathway (the death receptors Fas L and membranous TNF-α) (Özdemir, 2006, 
2007, 2011). 
Nonetheless, some researchers still consider MC as an enhancer of tumor development 
through their angiogenic effects, causing invasiveness and metastasis of tumor tissue 
(Özdemir, 2006). Some MC mediators such as heparin, IL-8 and tryptase are known to be 
responsible for angiogenesis (Ribatti, 2000). Yet, neither these mediators are the only 
known elements responsible from neoangiogenesis, nor are MCs the only resource. MCs 
also have a vast array of mediators, some of which have promoting, and others inhibitory 
effects on angiogenesis besides malignancies (Özdemir, 2006). The same  researchers 
consistently based their theories on pathological specimen observations, showing an 
association between increased MCD and the worst prognosis in some cancers such as 
endometrial cancer, leukemia as well as lymphomas (Ribatti, 2009; Molin, 2002). Our 
correspondences against this conviction have been well documented in recent literature 
(Özdemir, 2006). 
As summarized above, in this chaotic literature environment, our aim in this study was to 
investigate human MCC against NK- and lymphokine activated killer (LAK)-sensitive/ 
resistant human leukemia-lymphoma cells in short and long term coincubations by our 
established flow cytometric (FCM) cytotoxicity methods (Özdemir, 2003, 2007, 2011). 
2. Material and methods 
2.1 Mast cell (effector) development in methylcellulose and maintenance in 
suspension culture 
A colony forming unit (CFU) -Mast was produced in vitro by our modified method 
(Özdemir, 2007, 2011). From several discarded patient samples, human bone marrow (BM) 
mononuclear cells (≥5x104) were obtained and suspended in 0.3 ml Iscove's Modified 
Dulbecco's Medium (IMDM) containing %1 Fetal Bovine Serum (FBS) after Ficoll (Sigma, St. 
Louis, MO). Cells were put into 3 ml serum-free methylcellulose medium [MethoCult™ 
SFBIT H4236, StemCell Technologies, British Columbia, Canada], supplemented with 200 
ng/ml of SCF, 50 ng/ml of IL-6 and 1ng/ml of IL-3 (only at the beginning). All cytokines 
were purchased from Biosource, Camarillo, CA. We inoculated 0.3 ml of the mixed medium 
in the 12-well plate with a 16 gauge blunt needle and placed into an incubator. Every two 
weeks, the cells were fed with 0.3 ml new medium including 100 ng/ml of SCF and 50 
ng/ml of IL-6. Thirty or more cells were scored as CFU-Mast in situ on an inverted 
microscope after 4 weeks. Before culturing in suspension, MCs are retrieved from only CFU- 
Mast`s in the medium and dissolved with >2-fold volume of phosphate buffer solution 
including FBS %10 at 6th weeks. Cells are centrifuged at 250xG for 5 minutes. They are 
suspended and cultured in complete IMDM supplemented with 100 ng/ml of SCF, 50 
ng/ml of IL-6 and 2% FBS in 25cm2 flask up to 8th weeks. The culture was started with ≤104 
cells/ml and accumulated up to ≤2x106 cells/ml. The suspension culture was hemi-depleted 
every week and supplemented with 100 ng/ml of SCF and 50 ng/ml of IL-6.  
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2.2 Staining for verification of effector mast cells 
Verification of MCs was done by May-Grunwald-Giemsa, Wright-Giemsa, acid Toluidine 
Blue staining and immunophenotyping on FCM. In brief, a colony was lifted with 
Eppendorf micropipette and spun down at 600 rpm for 5 minutes in the 4th and 6th week. 
Viability was checked with a trypan blue exclusion test. Cells from colonies were stained 
with May-Grunwald-Giemsa and Wright-Giemsa for verification purposes (Fig.1A1-4). MCs 
were fixated with a Carnoy solution and incubated for 2 minutes with acid toluidine blue to 
confirm their tryptase content as well. Furthermore, MCs were immunophenotyped for all 
related markers in FCM at 4th-8th weeks (Fig.1B1-3, Table 1). All monoclonal antibodies 
(mAb) were purchased from Immunotech, Inc. (Westbrook, ME).  
 
 
Fig. 1. A1- 4. Wright- Giemsa slides are showing conjugate formation between mast cell and 
both tumor cells (effector-target doublets). A1-2 show conjugate formation between mast 
and Daudi cells. A3-4 depict conjugate formation between mast and Raji cells. 
 
 
Fig. 1. B1- 3. Phenotyping of 4- week- old human bone marrow -derived mast cells on flow 
cytometry is shown in a representative sample. B1 shows CD117 (c-kit) expression vs. SS 
(granularity) of mast cells. B2 demonstrates ≥98% of cells already stained with CD117 and 
became CD34 negative. B3 illustrates 93% of cells stained with CD33 and 76% of cells were 
positive for CD49d. [The human effector (mast) cells produced from bone marrow were 
absolutely negative for CD19 in this study.] 
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Surface Marker Expressions  4th-week              6th-week 8th-week 
CD14 0 % 0 % 0 % 
CD15 93 % 3 % 2 % 
CD19 0 % 0 % 0 % 
CD33 93 % 25 % 19 % 
CD34 7 % 1 % 1 % 
CD38 0 % 0 % 0 % 
CD44 93 % 85 % 84 % 
CD45 0 % 0 % 0 % 
CD49d 76 % 12 % 11 % 
CD117 (c-kit) 91 % 95 % 98 % 
HLA-DR 0 % 0 % 0 % 
Table 1. The phenotypic characterizations of 4- to 8- week-old human bone marrow- derived 
mast cells by flow cytometry in representative samples are shown.  
2.3 Target lymphoma and leukemia cells 
The human malignant B-lymphoblastoid cell lines such as Daudi/ Raji and erythroleukemia 
cell line K562, known as “LAK- sensitive” and “reference cells” in cytotoxicity studies, were 
utilized in this study. In several experiments we also utilized LAK- resistant human acute 
myeloid leukemia (AML) cell lines (HL-60, DAMI and Meg-01) and discarded AML patient 
samples were used. All cell lines were obtained from ATCC (Manassas, VA) and maintained 
in RPMI 1640 culture media, supplemented with 10% FBS. Before coincubation, target and 
effector cell viability were determined by the trypan blue exclusion test; a viability of 90% 
was required to proceed.  
2.4 Assessment of human MCC on FCM 
Cytotoxicity was assessed by two different FCM cytotoxicity techniques utilizing DIOC18 or 
mAb staining for target cell labeling (Özdemir, 2007, 2011). The basic strategy of two-color 
FCM assay involves labeling target cells with a fluorescent membrane dye DIOC18, in 
addition to staining with PI, to identify dead cells. Alternatively, a new three-color FCM 
approach called as “flow cytometric mast cell-mediated cytotoxicity assay (FCM-MCMCA) “ 
, which entails target cell marking with specific mAb (CD19) and with AnnV/PI colabeling 
to identify apoptotic/dead target cells, was used for some tumor cells. Briefly, we 
performed the following stepwise approach for analyzing the samples: 
2.5 Pre-labeling target leukemia cells with DIOC18 
A stock solution was prepared by dissolving DIOC18 (Sigma, St. Louis, MO) in DMSO (2 
mg/ml) overnight with agitation. The target cells (106cells/ ml) were incubated with 
10µg/ml of DIOC18 (final concentration) in 1 ml of PBS containing %3 FBS for 45 minutes at 
incubator. Then, target cells were washed with PBS three times to get rid of dye remnant. 
DIOC18 pre-labeling before coincubation was done for K562, Meg-01, HL-60, DAMI cells 
and the patient samples (Fig.1C1-E3). 
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Fig. 1. C1- E3: Target cell (DAMI) death is shown by new flow cytometric assay at 24h and 
48h in a representative sample. Identification of effector and target cells in 
alone/coincubation samples using target cell labeling (DIOC18) and cell size characteristics 
(FS) is shown in histograms at the first row. Spontaneous death and cytotoxicity evaluation 
of the cell populations alone or in co-incubation samples are shown with the rectilinear 
boxes of related histograms at the second and third rows. C1 shows location of effector-mast 
cell. Since effector cells are not pre-stained with DIOC18, they are DIOC18 negative and in a 
different area (Region G). C2 and C3 demonstrate the change in viability of effector cell 
alone population (DIOC18−/PI− viable cells: 94% and 91%; respectively) at 24h/48h. 
Spontaneous deaths in these effector alone samples are 6% and 9%; respectively. These 
histograms are obtained after gating on region G of a corresponding sample. D1 shows the 
target-DAMI cell population from target alone tube. As expected, target cells are very well-
marked with DIOC18 (Region J). D2 and D3 depict the viability of the target population alone 
(DIOC18+/PI− viable cells: 96% and 95%; respectively) at 24h and 48h. Spontaneous deaths in 
these samples are 4% and 5%; respectively. These histograms are obtained after gating on 
region J of a corresponding sample. E1 obtained from an experiment where mast cells are co-
incubated with DIOC18-positive DAMI cells at 2:1 effector/ target ratio. In this co-incubation 
sample; effector/target gatings are defined according to the target/effector alone (control) 
tubes. E2 depicts decrease in viability of previously gated target cells in J region of a 
corresponding co-incubation sample, 7% of them are stained with PI+ indicating necrotic 
killing (Region L2). In this representative sample, DAMI cell viability slightly decreased from 
96% in the control to 93% after 24h co-incubation. The 4% of spontaneous death increased up 
to 7% with cytotoxicity mediated by mast cells during 24h co-incubation. E3 shows obvious 
decrease in viability of previously gated target DAMI cells, as 26% of them are dead. In this 
representative sample, DAMI cell viability further decreased from 95% to 74% throughout 48h 
co-incubation. The necrotic populations increased from a corresponding 5% of spontaneous 
death to 26% kill mediated by mast cell cytotoxicity in the co-incubated sample.  
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2.6 Coincubation 
A few sets of human BM-derived MCs at 8th weeks of age, without any stimulation (PMA 
etc.) and human tumor targets were coincubated at certain effector/target ratios (1:1, 2:1, 4:1, 
5:1) short-term and long-term. Human MCs were coincubated in vitro with human LAK-
sensitive (K562, Daudi, Raji cells) and LAK- resistant tumor targets (Meg-01, HL-60, DAMI 
and patient cells) for the evaluation of human MCC. Tubes were centrifuged at 115xG for 5 
minutes and incubated at 37ºC in 5% CO2  for short- (2h) and long-term (up to 48h) period. 
Although MCC is well-known to take place after long-term incubation (>18h), 2h and 48h 
coincubation times were selected so as not to miss any possible cytotoxicity. And these 
experiments were repeated several times with a few sets of MC colonies on different times. 
Samples were tested in duplicates for reproducibility and reliability. 
2.7 Target lymphoma cell labeling with mAb and detection of death after coincubation 
Labeling target cells were done by two different methods in this study. As mentioned 
earlier, the first one is DIOC18 prelabeling for leukemia samples, which is being done before 
coincubation. The second technique is based on marking the lymphoma targets such as 
Daudi and Raji cells after co-incubation with 10µl of mouse anti-human PE conjugated CD19 
mAb (Immunotech, Westbrook, ME) for 20 minutes before staining for detection of death.  
Detection of apoptosis/death in target cells in mAb labeling technique was done by staining 
with AnnexinV (AnnV) and propidium iodide (PI) (TACS™ AnnexinV-FITC; R&D Systems, 
Minneapolis, MN) for 20 minutes before FCM acquisition. AnnV+ and/or PI+ events were 
analyzed from gating on the events in the target population of the control as well as 
coincubation samples. Ann V+ events represent early apoptotic population, AnnV+/ PI+ 
dead (late apoptotic or necrotic) cells (Fig.1F1-I2). In the DIOC18 prelabeling method, 
counterstaining with the nuclear dye PI (R&D Systems, Minneapolis, MN) of target cells was 
also done for 20 minutes before acquisition to discriminate between live and dead target 
cells. PI+ events represent dead cell population in FCM (Fig.1C1-E3).   
2.8 FCM acquisition and running 
FCM was performed using an EPICS-XL MCL (multicarousel) (Coulter, Miami, FL) 
equipped with an argon laser (15 mW) source operating at 488 nm. The emission of three 
fluorochromes was recorded through specific band pass filters: 525 nm for FITC (FL1), 575 
nm for PE (FL2), 620 nm for fluorospheres (FL3), and 675 nm for PI (FL4). The instrument 
was set for 4-color analysis. As the emission spectra of the three different dyes utilized in 
this bioassay interfere with one another, appropriate electronic compensations were 
adjusted by running individual cell populations stained with each dye consecutively 
through the EPICS. Once the compensations had been set, a gating was done on forward 
scatter (FS) (ordinate) versus log-scale fluorescence of mAb CD19 or DIOC18 (abscissa), to 
separate target cells from effector cells (Fig.1C1-I2). The FS gating was especially helpful for 
separating bigger DAMI and Meg-01 target cells from effector MCs. The log-scale 
fluorescence (CD19 or DIOC18) of abscissa was well enough to separate targets from 
effectors besides the aid of FS gatings. The different cell populations (target, effector and 
coincubated cells) were gated on with the help of isotype control samples. To measure 
target-cell death and apoptosis, CD19-/DIOC18- positive events were gated on, and analysis 
of log green fluorescence (AnnV) and/or log red fluorescence (PI) was performed depend 
on the cytotoxicity technique ( Fig.1C1-I2).  
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Fig. 1. F1- I2. Target (Daudi) cell kill, caused by mast cell- mediated cytotoxicity, is 
demonstrated by flow cytometric mast cell -mediated cytotoxicity assay (FCM-MCMCA) at 
12h in a representative sample. Quadrant gating and determination of populations in fig. 
1F1- H2 were defined by control samples consisting of target/effector alone tubes. The 
histograms in fig. 1G2-H2 were achieved from gating accordingly on target cell populations. 
1F1 shows location of effector-mast cell in the histograms of FCM-MCMCA. Effector cells 
are seen as CD19 negative (effector alone sample). 1F2 demonstrates spontaneous kill in 
effector cell population in control tube. 1G1 shows target-tumor cells location. As expected, 
the target cell population is well-marked with CD19 in the histogram and there is no effector 
cell (target alone sample) in the tube. 1G2 shows spontaneous kill in the target cell 
population of the control sample. It shows 92% viable (Annexin-/ PI-) target (Daudi) cells 
with total 8% spontaneous killing including early apoptotic plus necrotic kill. 1H1 
demonstrates co-incubated effector and target cells at 1:1 ratio after 12h (co-incubation 
sample). It reveals the changes in the target cell population in the quadrant J of the fig. 1G1 
in coincubated samples after cytotoxic kill. Compared to fig. 1G1, decrease in size and 
amount of the target cell population of 1H1 indicates killing due to mast cell –mediated 
cytotoxicity. Effector cells in this sample are not stained with CD19 and they are in a 
different area. However; it is hard to say anything about conjugate formation between target 
and effector cells (effector-target doublets) in the co-incubation sample, and it seems 
probable that it is happening earlier. The doublets probably form and immediately dissolve 
during the beginning of this process. Thus, there is no reflection of conjugate formation in 
fig. 1H1. 1H2 histogram of co-incubation sample was acquired after gating on the 
population in the quadrant J of fig. 1H1 and reflects the alterations in that co-incubated 
target population after cytotoxic kill. It depicts obvious decrease in viability of the target 
cells from 92% to 48%. It shows increased death up to 52 %, which 6 % of killing was 
necrotic-late apoptotic (Annexin+/PI+) and 46 % of killing was early apoptotic 
(Annexin+/PI-). Obviously, decline in viability of the target cell population from 92% to 
48% strongly reveals significant killing due to human mast cell- mediated cytotoxicity in 
vitro. Similarly, 1I1 shows further decrease in size and amount of the target cell population 
of 1G1 and 1H1 due to augmented cytotoxic kill at 2:1 ratio. And 1I2 demonstrates a 
decrease in viability of the target cell population from 92% to 37%, but death increased up to 
53% at a higher ratio.  
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2.9 FCM data analysis 
An average of 10,000 total events and 3,000 target cells were collected per sample. The 
gating for the target cells was based on the target-alone analysis and kept constant 
throughout all tubes to avoid exaggeration of the counts due to apoptotic body 
contamination. Cytotoxicity calculations were based on viable populations in target-alone 
(control) and co-culture (coincubated) tube analysis results. Viable target-cell percentage 
was determined, and calculations were based on the control-tube (target alone) values. 
Apoptotic and/or necrotic death happening in control tubes were identified as spontaneous, 
but those killed in coincubated tubes were identified as cytotoxic killing. We expressed the 
MCC as percentage based cytotoxicity: 
2.10 Percentage based cytotoxicity (%, PC) 
As mentioned, we defined MCC occurring in co-culture tube (coincubated sample) as 
percent (%, PC) cytotoxicity.  And cytotoxicity calculations were based on viable 
populations in target-alone (control) and co-culture tube analysis results.  
      
Control-viable cell%  – Coincubation-viable cell%
Percent Cytotoxicity PC =
Control-viable cell%
 
Our in vitro experiments were repeated several times (n=27) with a few sets of MC colonies. 
Samples were tested in duplicates for reproducibility and reliability (mean coefficients of 
variation (CV) of 1.1% (95% CI, 0.8- 1.7%); r2=0.93, and p<0.001). 
2.11 Comparison with chromium- 51Cr release assay (CRA) 
A standard assay was performed as previously described (Özdemir, 2007). Briefly, the assay 
is a standard 4h CRA using target cells that have been prelabeled with 100 μCi 51Cr (Perkin 
Elmer, Boston, MA) for 1h. Several concentrations of MCs were added to a fixed number of 
target cells (5,000) in a round bottom microtiter plate to a total volume of 0.2 ml. Following 
the 4h incubation, 0.1 ml of the supernatant was carefully harvested and counted on a 
scintillation counter (Packard, Downers Grove, IL). Maximum release was determined from 
wells including target cells and 10% sodium dodecyl sulfate in the medium. The PC was 
calculated using the following equation: (E–S)/(M–S)x100, where E is the experimental 
counts/minute, S is the spontaneous counts/minute and M is the maximum counts/minute. 
In the end, when we used some sets of our experimental data in comparing FCM 
cytotoxicity assays with CRA results, there was a significant correlation for PC (n=58; r= 
0.95; P<0.001), similar to our earlier studies (Özdemir, 2007, 2011). 
2.12 Cell staining with Wright/Giemsa for light microscopy  
At the end of the coincubation period, the sample was gently mixed and 10µl was used to 
prepare slides at room temperature without cytospinning. The slides were then stained with 
Wright/Giemsa. Conjugate formations between some tumor cells and MCs were seen 
(Fig.1A1-A4).  
2.13 Statistical analysis 
Unless otherwise specified, all data are presented as means±SEM. The significance of 
differences between spontaneous and cytotoxic kill was determined using the paired 
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Student’s t-test and/or Wilcoxon test. Correlations were estimated by Pearson correlation 
coefficients. Significance was considered as ≤0.05. All statistics were done using the 
Statistical Package for Social Sciences (SPSS-13 for Windows; Chicago, IL). 
3. Results 
This study demonstrated MCC against tumor cells by using human cells instead of murine 
effector/target cells. In vitro MCC against various tumor cells at different E:T ratios (1:1-5:1) 
was measured by FCM-MCMCA and DIOC18 methods on various periods (Table 2A-D).  
 
Pecentage Based Mast Cell- Mediated Cytotoxicity (%, PC) 
Cell characteristics %, PC on Coincubation Times 
LAK-sensitive Death  Type 2h 18h 48h 
Effector (Mast) control/alone 
Target (K562) control 
Coincubation (5:1) 
 
Spontaneous 
Spontaneous 
Cytotoxic 
N= 
P= 
2±1 
3±1 
4±2 
(3) 
NS 
1±1 
5±1 
7±1 
(9) 
NS 
3±1 
5±1 
18±2 
(9) 
NS 
LAK-resistant Death Type 2h 18h 48h 
Effector control /alone 
Target (DAMI) control 
Coincubation (5:1) 
Spontaneous 
Spontaneous 
Cytotoxic 
N= 
P 
1±1 
2±1 
9±1 
(3) 
NS 
2±1 
5±1 
19±2 
(9) 
NS 
3±1 
7±1 
24±2 
(9) 
NS 
Effector control 
Target (Meg-01) control 
Coincubation (5:1) 
Spontaneous 
Spontaneous 
Cytotoxic 
N= 
P= 
2±1 
1±0 
7±1 
(3) 
NS 
3±1 
5±1 
20±2 
(9) 
0.059 
3±1 
8±1 
27±4 
(9) 
0.031 
Effector control 
Target (HL-60) control 
Coincubation (5:1) 
 
Spontaneous 
Spontaneous 
Cytotoxic 
N= 
P= 
3±1 
5±1 
6±2 
(3) 
NS 
4±1 
8±1 
18±1 
(9) 
0.050 
4±1 
11±2 
39±3 
(9) 
0.011 
Effector control 
Target (Patients`) control 
Coincubation (5:1) 
 
Spontaneous 
Spontaneous 
Cytotoxic 
N= 
P= 
1±1 
2±1 
5±1 
(6) 
NS 
3±1 
8±1 
20±1 
(9) 
NS 
4±1 
13±1 
22±2 
(9) 
NS 
The death/killings (percentage based cytotoxicity) in this table reflect the death at a 5:1 ratio in this study. 
Spontaneous kill reflects the death in target or effector alone tubes. Cytotoxic death shows the target cell 
death by only mast cell- mediated cytotoxicity in coincubation sample. The percentage based cytotoxicity  
was calculated according to the given formula in the methods. All values are given as mean±SEM. P values  
reflect the  significance of differences between spontaneous and mast cell mediated cytotoxic killing. N 
denotes the number of  experiments were repeated in each series. NS means not significant. 
Table 2A. In vitro human mast cell -mediated cytotoxicity measured by DIOC18 method 
against different human tumor cells is shown. 
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Percentage Based Human Mast Cell- Mediated Cytotoxicity (%, PC) 
Cell characteristics %, PC on Coincubation Times 
LAK-sensitive Death Type 2h 12h 24h 
Effector (Mast) control 
Target (Daudi) control 
Coincubation (1:1) 
 
Spontaneous 
Spontaneous 
Cytotoxic 
N= 
P= 
3 ± 1 
2 ± 1 
21 ± 2 
(9) 
0.048 
4 ± 1 
3 ± 1 
49 ± 2 
(9) 
0.009 
5 ± 2 
6 ± 2 
53 ± 3 
(9) 
0.005 
Effector control/alone 
Target (Daudi) control/alone 
Coincubation (2:1) 
 
Spontaneous 
Spontaneous 
Cytotoxic 
N= 
P= 
4±1 
4±1 
31±1 
(3) 
0.039 
3 ± 2 
3 ± 1 
57± 2 
(9) 
0.001 
4 ± 2 
5 ± 2 
63 ± 3 
(9) 
0.001 
Effector control 
Target (Daudi) control 
Coincubation (4:1) 
 
Spontaneous 
Spontaneous 
Cytotoxic 
N= 
P= 
4±1 
2±1 
36±1 
(9) 
0.030 
3 ± 2 
4 ± 1 
59± 2 
(9) 
0.001 
4 ± 2 
6 ± 2 
67 ± 3 
(9) 
0.001 
Effector control /alone 
Target (Raji) control /alone 
Coincubation (1:1) 
 
Spontaneous 
Spontaneous 
Cytotoxic 
N= 
P= 
2±1 
3±1 
13±1 
(9) 
0.049 
3 ± 1 
4 ± 1 
16 ± 1 
(9) 
0.046 
6 ± 1 
8 ± 3 
47± 3 
(9) 
0.008 
Effector alone 
Target (Raji) alone 
Coincubation (2:1) 
 
Spontaneous 
Spontaneous 
Cytotoxic 
N= 
P= 
5±1 
7±1 
19±1 
(3) 
0.044 
3 ± 1 
5 ± 1 
26 ± 1 
(9) 
0.016 
4 ± 1 
9 ± 3 
67± 3 
(9) 
0.001 
Effector alone 
Target (Raji) alone 
Coincubation (4:1) 
 
Spontaneous 
Spontaneous 
Cytotoxic 
N= 
P= 
4±1 
3±1 
19±1 
(9) 
0.040 
6 ± 1 
7 ± 1 
30 ± 1 
(9) 
0.014 
5 ± 1 
8 ± 3 
69± 3 
(9) 
0.001 
The death/killings (percentage based cytotoxicity) in this table reflect the death at 1:1, 2:1, 4:1 ratios in 
this study. Spontaneous kill reflects the death in target or  effector alone tubes. Cytotoxic death shows 
the target cell death by only mast cell-mediated cytotoxicity in the coincubation sample. The percentage 
based  cytotoxicity was calculated according to the given formula in the methods. All values are given 
as mean±SEM. P values reflect the significance of differences between spontaneous and mast cell 
mediated cytotoxic killing. N denotes the number of  experiments were repeated in each series. NS 
means not significant. 
Table 2B. In vitro human mast cell-mediated cytotoxicity % (percentage based killing) 
measured by FCM-MCMCA against human LAK-sensitive tumor cells at different ratios 
and time periods (2h- 24h) are shown.  
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Percentage Based Human Mast Cell- Mediated Cytotoxicity (%, PC) 
Cell characteristics %, PC on Coincubation Times 
LAK-sensitive Death  Type 2h 12h 18h 24h 48h 
Effector (Mast) control/alone 
Target (K562) control 
Coincubation (2:1) 
Spontaneous 
Spontaneous 
Cytotoxic 
N= 
P= 
2±1 
3±1 
0±1 
(3) 
NS 
4±1 
4±1 
6±1 
(9) 
NS 
3±1 
5±1 
6±1 
(9) 
NS 
5±1 
6±1 
14±1 
(9) 
NS 
7±1 
5±1 
16±2 
(9) 
NS 
Effector control 
Target (Daudi) control 
Coincubation (2:1) 
Spontaneous 
Spontaneous 
Cytotoxic 
N= 
P= 
4±1 
4±1 
30±1 
(3) 
0.030 
3 ± 2 
3 ± 1 
57± 2 
(9) 
0.001 
3 ± 2 
4 ± 1 
59± 2 
(9) 
0.001 
4 ± 2 
5 ± 2 
63 ± 3 
(9) 
0.001 
4 ± 2 
8 ± 2 
65 ± 3 
(9) 
0.001 
Effector control 
Target (Raji) control 
Coincubation (2:1) 
 
Spontaneous 
Spontaneous 
Cytotoxic 
N= 
P= 
5±1 
7±1 
19±1 
(3) 
0.044 
2 ± 1 
5 ± 1 
26 ± 1 
(9) 
0.016 
2 ± 1 
7 ± 1 
46 ± 1 
(9) 
0.006 
4 ± 1 
9 ± 3 
67± 3 
(9) 
0.001 
4 ± 1 
10 ± 3 
75± 3 
(9) 
0.001 
LAK-resistant Death Type 2h 12h 18h 24h 48h 
Effector (Mast) control/alone 
Target (DAMI) control/alone 
Coincubation (2:1) 
 
Spontaneous 
Spontaneous 
Cytotoxic 
N= 
P= 
5±1 
2±1 
6±1 
(3) 
NS 
3±1 
5±1 
15±2 
(6) 
NS 
4±1 
5±1 
17±2 
(6) 
NS 
6±1 
7±1 
20±2 
(6) 
NS 
8±1 
7±1 
22±2 
(6) 
NS 
Effector control 
Target (Meg-01) control 
Coincubation (2:1) 
 
Spontaneous 
Spontaneous 
Cytotoxic 
N= 
P= 
3±1 
1±0 
4±1 
(3) 
NS 
5±1 
6±1 
14±2 
(5) 
NS 
4±1 
5±1 
18±2 
(5) 
NS 
6±1 
8±1 
22±4 
(5) 
NS 
6±1 
8±1 
25±4 
(5) 
0.039 
Effector control 
Target (HL-60) control 
Coincubation (2:1) 
 
Spontaneous 
Spontaneous 
Cytotoxic 
N= 
P= 
3±1 
5±1 
5±1 
(3) 
NS 
6±1 
7±1 
13±1 
(6) 
NS 
3±1 
8±1 
16±1 
(6) 
NS 
5±1 
9±2 
28±3 
(6) 
0.034 
5±1 
11±2 
36±3 
(6) 
0.019 
Effector control 
Target (Patients`) control 
Coincubation (2:1) 
 
Spontaneous 
Spontaneous 
Cytotoxic 
N= 
P= 
3±1 
2±1 
5±1 
(6) 
NS 
2±1 
6±1 
15±1 
(6) 
NS 
4±1 
8±1 
18±1 
(6) 
NS 
6±1 
10±1 
20±2 
(6) 
NS 
6±1 
13±1 
21±2 
(6) 
NS 
The death/killings (percentage based cytotoxicity) in this table reflect the death at a 2:1 ratio in this 
study. Spontaneous kill reflects the death in target or  effector alone tubes. Cytotoxic death shows the 
target cell death  by only mast cell-mediated cytotoxicity in the coincubation sample. The percentage 
based  cytotoxicity  was calculated should be given formula. All values are given as mean±SEM. P 
values reflect the significance of differences  between spontaneous and mast cell mediated cytotoxic 
killing. N denotes the number of  experiments were repeated in each series. NS means not significant. 
Table 2C. In vitro human mast cell -mediated cytotoxicity (%, PC) against different human 
tumor cells measured by both cytotoxicity assays is shown at various periods. 
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Cell 
Types 
Percentage Based Human Mast Cell- Mediated Cytotoxicity (%) 
12h 24h 
Early 
Apoptotic 
Late 
Apoptotic 
Total 
Killing 
Early 
Apoptotic 
Late 
Apoptotic 
Total 
Killing 
Daudi 7% 50% 57 % 23% 40% 63 % 
Raji 8 % 18% 26 % 27% 40% 67 % 
Table 2D. The distribution of mean killing (%, PC) measured by FCM-MCMCA in human 
LAK-sensitive tumor cells at 2:1 ratio on different coincubation times in a representative 
sample.  
In the literature, MCC did not seem to be very effective against some types of LAK-sensitive 
tumor cells, such as K562 and YAC-1 (Henderson, 1981; Ghiara, 1985; Richards 
1988).Consistently, there was not significant killing (18% killing at most) in NK-/LAK-
sensitive K562 cells even with 5:1 ratio at 48h (Table 2A,C). These findings supported well-
known resistance to MCC by some LAK-sensitive cells. However, human MCC for first time 
was found to be very effective against different type of LAK-sensitive cells, such as Daudi 
and Raji, in this study. As shown in these studies, most of the total killing of both human 
target cells was necrotic kill and it increased over time. Interestingly, Raji killing, especially 
necrotic, apparently maximized at 24h, even though Daudi cell killing stayed almost stable 
and peaked at 12h. Both LAK-sensitive Daudi and Raji cell death were statistically 
significant between 2h-48h, compared to spontaneous killing. In vitro human MCC against 
LAK-sensitive cells at different ratios/times was shown in table 2B-C.  
Moreover, in this study the FCM-MCMCA method allowed us to separate cytotoxic killing 
into different stages, early and late apoptotic (necrotic) kill. And distribution of apoptotic 
type killing according to the cell lines at 12h and 24h was shown at 2:1 ratio (Table 2D). 
Early apoptotic cell death up to 46% was also detected in the representative samples 
(Fig.1H2,I2), indicating the role of pro-apoptotic components of MC granules in human 
MCC.  
Although at 2h/12h/18h there was some killing, statistically significant killing in LAK-
resistant cells such as Meg-01 and HL-60 cells was demonstrated with both 2:1 and 5:1 ratios 
at 48h (Table 2A,C). In HL-60 cells, there was a statistically significant degree of kill at 18h 
(ratio 5:1) and 24h (ratio 2:1) as well. Moreover, the AML patient samples seemed to be very 
resistant to MCC. In patient cells, there was a fair amount of killing (≤25 %) but was not 
statistically significant (Table 2A,C). Insignificant killing in patient samples and LAK-
resistant cells, probably due to small number of sample, but it was noticeably important. 
This is the first study demonstrating human MCC against some human LAK-resistant cells 
too. 
After 2h/12h coincubations, neither at 2:1 nor at 5:1 ratios was there significant killing in 
any experiments except for Daudi and Raji cells. In LAK-sensitive Daudi/Raji cells, 
statistically significant death at different rates was demonstrated and remained significant 
from 2h-48h coincubation (Table 2B-C). Concurrently, short term MCC (≤18h) was observed 
in patient samples as well as DAMI/HL-60/Meg-01 cells in this study, although MCC in the 
long term is well-known. We even observed some degree of cytotoxicity in very short-term 
incubation (2h) in DAMI/Meg-01 cells, although there was not statistically significant 
killing. The killing detected between 2h-48h in all LAK-resistant cells including patients’ 
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was close to statistical significance, partly due to an inadequate number of experiments 
(Table 2A,C). In overall; Daudi/Raji/Meg-01 and HL-60 cell deaths were found to be 
statistically significant at different periods in long term, compared to spontaneous (control) 
killing (Table 2A-C). Thus, these findings reveal human MC`s cytotoxic capacity against 
human LAK-resistant/-sensitive cells.   
Briefly, interestingly, MCs did not seem to be very effective against some type of human 
NK-/LAK-sensitive cells such as K562; but LAK-resistant cells including Meg-01/HL-
60/DAMI/patients’ were killed somewhat effectively by MCC.  
The ability to study MCC in longer coincubation times (≤48h), in addition to shorter 
coincubation times (2h-18h), is another advantage of our established FCM methods in this 
study. This appears to be a drawback for CRA as well as other methods utilizing dyes such 
as fluorochromes (PKH-26) due to increased risk in release of 51Cr or dye leakage, which 
results in staining of other populations. Nevertheless, our applications are potentially 
important for studying certain apoptotic pathways that take longer to become operational, 
such as membranous TNF-α-induced apoptosis, which is believed to be one of most 
important components of MCC. Membranous TNF-α has been shown to kill WEHI-
164/L929/Raji cells in 24h assays (Henderson, 1981; Ghiara, 1985; Richards 1988; Heikkilä, 
2008; Özdemir, 2003, 2006).   
In this study, our results were found to be reproducible and reliable when experiments 
repeated (mean coefficients of variation (CV) of 1.1%).  Incremental increase in MCC 
detected at different ratios/times shows reproducibility and reliability of our methods 
(Table 2A-C). When our flow cytometric data compared with CRA results, there was a 
significant correlation (n=104, r=0.82, p<0.001), similar to our earlier studies (Özdemir, 2003, 
2007, 2011). 
In addition, Wright-Giemsa slides showed conjugate formations between MC and some 
tumor cells (MC-target cell doublets), indicating possible initial steps of human MCC, 
perhaps via cell-to-cell contact thru their membranous components such as membranous 
TNF-α/Fas Ligand (Fig.1A1-4).  
4. Discussion 
This study first of all demonstrated human MCC against human tumor targets by two 
different approaches that were very comparable to CRA. These are established and reliable 
methods elucidating MCC by a two- and three-color FCM assays using DIOC18 and mAb 
target-cell marking, respectively. Our research experiences with these methods have been 
recently published (Özdemir, 2003, 2007, 2011). 
As mentioned above, murine MCC against lysis-sensitive murine tumor cell lines (WEHI–
164/L929) in long term was previously well demonstrated (Henderson, 1981; Ghiara, 1985; 
Richards 1988). Nevertheless, to the best of our knowledge, this is the first study using 
human BM-derived effector MCs against human tumor cells to show and verify short- and 
long-term human MCC in vitro. Even significant kill in different LAK-sensitive/-resistant 
cells was also demonstrated for the first time. MCC was shown to be effective against 
different types of NK-/LAK-sensitive Daudi/Raji cells, but not to K562 cells or LAK-
resistant cells. These findings are consistent with earlier murine studies demonstrating 
murine MCC against lysis-sensitive cells. Like murine cells, Daudi/Raji are also known to be 
somewhat lysis (TNF-α)-sensitive, and this explains statistically significant and mostly 
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necrotic killing in Daudi/Raji, which probably reflects pro-necrolytic characteristics of 
MCC.  
Early cell death of LAK-sensitive/-resistant cells in our experiments detected from 2h 
indicated human MCC occurring in short-term coincubation. These results strongly suggest 
a possible contribution of a fast-acting secretory pathway via the exocytosis of pro-apoptotic 
granules of MCs to the human MCC. Accordingly, these findings verify the recent literature 
suggestive of MC-induced apoptosis in smooth muscle cell, cardiomyocytes and endothelial 
cells (Leskinen, 2003; Heikkilä, 2008).  
The killing at various coincubation times in all LAK-resistant cells including patient cells 
was close to statistical significance partly due to an inadequate number of experiments. 
However, it was still noticeably important since these cells are known to be resistant to even 
LAK cells, and they are not essentially TNF-α sensitive cell. Thus our results also indicate a 
role for MC as a contributory effector cell in cellular immune surveillance of human innate 
immunity, resembling recently reported studies (Marshall, 2004; Özdemir, 2006). 
Contrary to the findings of this in vitro study, MC availability in tissues and tumor stroma 
has still been controversial. The important point is here: increased tissue MCD could be 
primary and/or secondary since MCD is also found to be increased physiologically around 
healing tissue (Özdemir, 2006). MCs might be just as a reflection of generalized 
inflammatory reaction as well. For instance; the infiltration of MCs was thought to be a 
reflection of the host inflammatory response and is favorable prognostic factor in diffuse 
large B-cell lymphoma (Hedström, 2007). Similarly, MCs were believed to represent reactive 
cell types involve in the pathophysiology of the host reaction in lymphoma (Sharma, 1992). 
MCs also accumulate at sites of tumor growth in response to numerous chemoattractants or 
mediators. For example, CCL5/CXCR3 chemokines in lymphoma and tumor-derived stem 
cell factor and CD30 expressions lead to tumor growth and MCD in tumor tissues (Fischer, 
2003). While evaluating the tumor-MC relationship, not only the MCD, but several other 
factors, such as the relationship of MCs with other stromal (fibroblasts, endothelial) and 
inflammatory cells should also be considered (Aldinucci, 2010). Hence it is important to find 
an answer to the following question: can the increased MCD be a result of tumor 
progression or a cause of tumor progression and a poor prognosis? Then the next question 
becomes, is the MC really an active player or an innocent passerby in a tumor stroma? 
Increased MCD in the tumor stroma was assumed to be a stimulator of tumor progression 
through angiogenesis. As with other tumors; there are also conflicting results about the role 
of MCD and its relation to microvessel density (MVD) in lymphoma/leukemia (Özdemir, 
2006). In addition, lymphoma progression is recently considered to be potentiated by at least 
two distinct angiogenic mechanisms. Autocrine stimulation of tumor cells via expression of 
vascular endothelial growth factor (VEGF) and VEGF receptors by lymphoma cells, as well 
as paracrine influences of proangiogenic tumor stroma on both local neovascularization and 
recruitment of circulating BM-derived progenitors (Ruan, 2009).  Similarly, isolated AML 
blasts were shown to overexpress the VEGF/VEGFR–2 pathway, which can promote the 
growth of leukemic blasts in an autocrine and paracrine manner (Mesters, 2001). Yet, in 
some literature the following are hematological tumors in which MCD correlates with MVD: 
B-cell non-Hodgkin lymphoma, HL, follicular/angioimmunoblastic T-cell lymphoma, and 
B-cell chronic lymphocytic leukemia (Ribatti, 1998; Fukushima, 2001; Ribatti, 2009; Tripodo, 
2010; Taskinen, 2010). And human tumors in which MCD is supposed to correlate with a 
poor prognosis include HL, diffuse large B-cell lymphoma, follicular and 
angioimmunoblastic T-cell lymphoma (Molin, 2002; Gratzinger, 2007; Ribatti, 2009; 
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Taskinen, 2010;). Amazingly, in some studies, human tumors in which MCD is supposed to 
correlate with a good prognosis include HL, diffuse large B-cell lymphoma, and follicular 
lymphoma (Koster, 2005; Hedström, 2007; Rygoł, 2007;Ribatti, 2009;). Although it is hard to 
explain these conflicting results above and in the literature, they may be associated with 
different methodologies used in studies such as timing of biopsy (e.g. doing in early instead 
of late stage of tumor), the tumor type, as well as environmental factors surrounding that 
tumor (Özdemir, 2006). Only observing increased MCD in various tumors with good or bad 
prognosis on pathological specimens seems to be far behind to explain the real role of MCs. 
The net effect of MCs on tumor growth, therefore, is likely to be the result of multiple 
interactions between MC, tumor, and associated inflammatory cells with their signaling 
pathways, and adjacent stromal cells such as vascular endothelium and fibroblasts (Ribatti, 
1998; Özdemir, 2006; Ribatti, 2009; Aldinucci, 2010).  
Consequently, antiangiogenic strategies have recently become an important therapeutic 
modality for solid tumors. And MCs have been thought of as a new target for the adjuvant 
treatment of tumors through the selective inhibition of angiogenesis, tissue remodeling and 
tumor promoting molecules. Preliminary studies with cromolyn in mice mammary 
adenocarinoma and pancreatic cancer therapy was ineffective. Although some therapeutics 
like alemtuzumab were also given as an example of antiangiogenic treatment success, it is 
known as an anti-myeloid cell antiangiogenic agent used for the treatment of ovarian cancer, 
not an anti-MC agent (Ruan, 2009). Beside MCs and myeloid cells, Tie2-expressing 
monocytes and vascular leukocytes have recently been shown as new targets in the 
regulation of tumor associated angiogenesis (De Palma, 2007). In the age of targeted 
therapy, studies of the targeting MCs` role in cancer might have direct clinical consequences 
and should be further elucidated via the use of histopathological and complex biological 
models. 
Since the aim of this study was basically to show MCC using human effector/target cells, 
the mechanisms and specificity of human MCC were not evaluated in this study. Our 
studies still continue studying MC-tumor cell relations and the characteristics of MCC on 
human pathological biopsy specimens. We hypothesize that human MCC may happen thru 
non-secretory pathway (cell-to-cell contact) of membranous TNF-α/Fas L, and secretory 
pathway via released mediators like soluble TNF-α, granzymes and chymase. Simply, MCC 
happens via pro-apoptotic/-necrolytic granules of MCs in the short term, as well as through 
its membranous components (non-secretory pathway of MCC) in the long term as shown in 
this study. Consistently, observing effector-target doublets on Wright-Giemsa slides of this 
study might suggest the importance of cell-to-cell contact in this process. The mechanisms 
with characteristics of human MCC against human tumor cells, as well as the role of MC 
mediators, are discussed by us in detail somewhere (Özdemir, 2006). 
5. Conclusion  
Our findings in this study verify possible anti-tumor role of MC as a contributory effector 
cell to NK and other cytotoxic cells in immunosurveillance within human innate immunity. 
As current literature is still very confusing regarding MC`s role in and around the tumor 
tissue, this in vitro study may help enlighten its interactions with tumor cells and trigger 
new explanatory in vitro/in vivo studies like, for example, delineating the killing 
mechanisms of MCC. 
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These conflicting reports might indicate that there seem to be other factors determining the 
relationship between MCD and tumor progression. The conflicting results may also depend 
on wide variations in timing, tumor types/stages, methodologies, and the chemotherapy 
application as well. Importantly, some studies are not able to reflect the direct effects of MCs 
on tumor biology because many patients receive adjuvant chemotherapy in the time of 
sampling. So, some of the effects can be accounted for by the therapeutic response to 
chemotherapy. Nonetheless, by only observing increased MCD in and around a tumor, 
making a correlation between good or bad prognosis and specimens seems inadequate to 
explain their real role.  
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